{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:40:47Z","timestamp":1794249647830,"version":"4.9.0"},"reference-count":54,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medicine by Design","award":["MbDSP-2021-01"],"award-info":[{"award-number":["MbDSP-2021-01"]}]},{"DOI":"10.13039\/501100000024","name":"canadian institutes of health research","doi-asserted-by":"publisher","award":["PJK-175385"],"award-info":[{"award-number":["PJK-175385"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"canadian institutes of health research","doi-asserted-by":"publisher","award":["PJK-179825"],"award-info":[{"award-number":["PJK-179825"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Med Decis Making"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is a novel cell therapy for treating non-Hodgkin lymphoma. The development of CAR T-cell therapy has transformed oncology treatment by offering a potential cure. However, due to the high cost of these therapies, and the large number of eligible patients, decision makers are faced with difficult funding decisions. Our objective was to assess the cost-effectiveness of tisagenlecleucel for adults with relapsed\/refractory diffuse large B-cell lymphoma in Canada using updated survival data from the recent JULIET trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed an individual-simulated discrete event simulation model to assess the costs and quality-adjusted life-years (QALY) of tisagenlecleucel compared with salvage chemotherapy. Survival estimates were obtained from a published clinical trial and retrospective analysis. If patients remained progression free for 5\u2009y, they were assumed to be in long-term remission. Costing and utility data were obtained from reports and published sources. A Canadian health care payer perspective was used, and outcomes were modeled over a lifetime horizon. Costs and outcomes were discounted at 1.5% annually, with costs reported in 2021 Canadian dollars. A probabilistic analysis was used, and model parameters were varied in 1-way sensitivity analyses and scenario analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After we incorporated the latest clinical evidence, tisagenlecleucel led to an additional cost of $503,417 and additional effectiveness of 2.48 QALYs, with an incremental cost-effectiveness ratio of $202,991 compared with salvage chemotherapy. At a willingness-to-pay threshold of $100,000\/QALY, tisagenlecleucel had a 0% likelihood of being cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At the current drug price, tisagenlecleucel was not found to be a cost-effective option. These results heavily depend on assumptions regarding long-term survival and the price of CAR T. Real-world evidence is needed to reduce uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>For patients with diffuse large B-cell lymphoma who failed 2 or more lines of systemic therapy, CAR T was not found to be a cost-effective treatment option at a willingness-to-pay threshold of $100,000. These results heavily depend on the expected long-term survival. The uncertainty in the model may be improved using real-world evidence reported in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0272989x241234070","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T02:26:28Z","timestamp":1710469588000},"page":"296-306","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis"],"prefix":"10.1177","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-9622","authenticated-orcid":false,"given":"Lisa","family":"Masucci","sequence":"first","affiliation":[{"name":"Toronto Health Economics and Technology Assessment Collaborative, Toronto General Hospital, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Waterloo, Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tully","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Waterloo, Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeny","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Guelph, Guelph, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0871-8773","authenticated-orcid":false,"given":"Tom","family":"McFarlane","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Waterloo, Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-3057","authenticated-orcid":false,"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, Toronto, ON, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[{"name":"Toronto Health Economics and Technology Assessment Collaborative, Toronto General Hospital, ON, Canada"},{"name":"School of Pharmacy, University of Waterloo, Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"bibr1-0272989X241234070","unstructured":"Canadian Cancer Society. Diffuse large B-cell lymphoma. 2019. [Available from: Accessed 20 October, 2022]."},{"key":"bibr2-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"bibr3-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"bibr4-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"bibr5-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.144"},{"key":"bibr6-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.5421"},{"key":"bibr7-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S145039"},{"key":"bibr8-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"bibr9-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283"},{"key":"bibr10-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5BT1215-556RR"},{"key":"bibr11-0272989X241234070","volume-title":"Regulatory Decision Summary\u2014Kymriah","author":"Government of Canada","year":"2019"},{"key":"bibr12-0272989X241234070","volume-title":"Kymriah (tisagenlecleucel)","author":"US Food and Drug Administration","year":"2019"},{"key":"bibr13-0272989X241234070","volume-title":"Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations","author":"Canadian Agency for Drugs and Technologies in Health","year":"2019"},{"key":"bibr14-0272989X241234070","volume-title":"Tisagenlecleucel for Diffuse Large B-cell Lymphoma: Economic Review Report","author":"Canadian Agency for Drugs and Technologies in Health","year":"2019"},{"key":"bibr15-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"bibr16-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"bibr17-0272989X241234070","unstructured":"Merative. IBM Micromedex RED BOOK Online. 2022. Available from: www.micromedexsolutions.com"},{"issue":"3","key":"bibr18-0272989X241234070","first-page":"89","volume":"16","author":"Ellis K","year":"2021","journal-title":"Healthc Policy"},{"key":"bibr19-0272989X241234070","volume-title":"Discrete Event Simulation for Health Technology Assessment","author":"Caro J","year":"2016"},{"key":"bibr20-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"bibr21-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30739"},{"key":"bibr22-0272989X241234070","volume-title":"Tisagenlecleucel for Treating Relapsed or Refractory Diffuse Large B-cell Lymphoma: Single Technology Appraisal Evidence Assessment Group Report","author":"Corbett MS","year":"2018"},{"key":"bibr23-0272989X241234070","volume-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","author":"Canadian Agency for Drugs and Technologies in Health","year":"2017"},{"key":"bibr24-0272989X241234070","volume-title":"Cost-effectiveness of Chimeric Antigen Receptor T-cell Therapy for Treating Large B-cell Lymphoma Patients in Canada","author":"Ellis K.","year":"2020"},{"key":"bibr25-0272989X241234070","volume-title":"Chimeric Antigen Receptor T-cell Therapy for B-cell Cancers: Effectiveness and Value Final Evidence Report","author":"Institute for Clinical and Economic Review","year":"2018"},{"key":"bibr26-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"bibr27-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.498"},{"key":"bibr28-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"bibr29-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0558-5"},{"key":"bibr30-0272989X241234070","unstructured":"Statistique Canada. Life tables, Canada, provinces and territories. 2021. Available from: https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/84-537-X. [Accessed 2022]."},{"key":"bibr31-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"bibr32-0272989X241234070","volume-title":"Ontario Case Costing Initiative: Cost Analysis Tool","author":"Ontario Health","year":"2018"},{"key":"bibr33-0272989X241234070","volume-title":"Schedule of Benefits: Physician Services under the Health Insurance Act","author":"Ontario","year":"2022"},{"key":"bibr34-0272989X241234070","volume-title":"Ontario Drug Benefit: Formulary Search","author":"Ontario","year":"2022"},{"key":"bibr35-0272989X241234070","volume-title":"2017 Hospital per Diem Rates Using 2015-16 Canadian MIS Database (CMDB) Data","author":"Canadian Institute for Health Information","year":"2017"},{"key":"bibr36-0272989X241234070","volume-title":"Interprovincial Billing Rates for Designated High Cost Transplants Effective for Discharges on or after April 1, 2020","author":"Ontario","year":"2020"},{"key":"bibr37-0272989X241234070","unstructured":"Post-treatment monitoring frequency discussion with clinician. Toronto (Canada); 2021."},{"key":"bibr38-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2019.05.002"},{"key":"bibr39-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2835-7"},{"key":"bibr40-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121759"},{"key":"bibr41-0272989X241234070","unstructured":"Statistics Canada. Consumer Price Index, by province. 2022. Available from: https:\/\/www.statcan.gc.ca\/en\/subjects-start\/prices_and_price_indexes\/consumer_price_indexes"},{"key":"bibr42-0272989X241234070","unstructured":"Organisation for Economic Co-operation and Development. Purchasing power parities (PPP). 2022. Available from: https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm [Accessed August, 2022]."},{"key":"bibr43-0272989X241234070","volume":"53","author":"Lin VW","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"bibr44-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.076"},{"key":"bibr45-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11098"},{"key":"bibr46-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003503"},{"key":"bibr47-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"bibr48-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr49-0272989X241234070","volume-title":"Axicabtagene Ciloleucel for Diffuse Large B-cell Lymphoma: Economic Review Report","author":"Canadian Agency for Drugs and Technologies in Health","year":"2019"},{"key":"bibr50-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1808981"},{"key":"bibr51-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"bibr52-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.06.011"},{"key":"bibr53-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.005"},{"key":"bibr54-0272989X241234070","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1922066"}],"container-title":["Medical Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X241234070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0272989X241234070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X241234070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:02:43Z","timestamp":1777658563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0272989X241234070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/0272989X241234070"],"URL":"https:\/\/doi.org\/10.1177\/0272989x241234070","relation":{},"ISSN":["0272-989X","1552-681X"],"issn-type":[{"value":"0272-989X","type":"print"},{"value":"1552-681X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}